ID   4F2_HUMAN               Reviewed;         630 AA.
AC   P08195; Q13543;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 3.
DT   10-MAY-2017, entry version 198.
DE   RecName: Full=4F2 cell-surface antigen heavy chain;
DE            Short=4F2hc;
DE   AltName: Full=4F2 heavy chain antigen;
DE   AltName: Full=Lymphocyte activation antigen 4F2 large subunit;
DE   AltName: Full=Solute carrier family 3 member 2;
DE   AltName: CD_antigen=CD98;
GN   Name=SLC3A2; Synonyms=MDU1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3476959; DOI=10.1073/pnas.84.18.6526;
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RT   "Molecular cloning of complementary DNAs encoding the heavy chain of
RT   the human 4F2 cell-surface antigen: a type II membrane glycoprotein
RT   involved in normal and neoplastic cell growth.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:6526-6530(1987).
RN   [2]
RP   ERRATUM, AND SEQUENCE REVISION.
RA   Quackenbush E., Clabby M., Gottesdiener K.M., Barbosa J., Jones N.H.,
RA   Strominger J.L., Speck S., Leiden J.M.;
RL   Proc. Natl. Acad. Sci. U.S.A. 84:8618-8618(1987).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RX   PubMed=3036867;
RA   Teixeira S., di Grandi S., Kuehn L.C.;
RT   "Primary structure of the human 4F2 antigen heavy chain predicts a
RT   transmembrane protein with a cytoplasmic NH2 terminus.";
RL   J. Biol. Chem. 262:9574-9580(1987).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
RP   INDUCTION.
RC   TISSUE=Fibroblast;
RX   PubMed=3480538; DOI=10.1073/pnas.84.24.9204;
RA   Lumadue J.A., Glick A.B., Ruddle F.H.;
RT   "Cloning, sequence analysis, and expression of the large subunit of
RT   the human lymphocyte activation antigen 4F2.";
RL   Proc. Natl. Acad. Sci. U.S.A. 84:9204-9208(1987).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALTERNATIVE SPLICING (ISOFORM 2),
RP   TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=3265470; DOI=10.1128/MCB.8.9.3809;
RA   Gottesdiener K.M., Karpinski B.A., Lindsten T., Strominger J.L.,
RA   Jones N.H., Thompson C.B., Leiden J.M.;
RT   "Isolation and structural characterization of the human 4F2 heavy-
RT   chain gene, an inducible gene involved in T-lymphocyte activation.";
RL   Mol. Cell. Biol. 8:3809-3819(1988).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION, SUBUNIT, AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=11557028; DOI=10.1016/S0005-2736(01)00384-4;
RA   Yanagida O., Kanai Y., Chairoungdua A., Kim D.K., Segawa H., Nii T.,
RA   Cha S.H., Matsuo H., Fukushima J., Fukasawa Y., Tani Y., Taketani Y.,
RA   Uchino H., Kim J.Y., Inatomi J., Okayasu I., Miyamoto K., Takeda E.,
RA   Goya T., Endou H.;
RT   "Human L-type amino acid transporter 1 (LAT1): characterization of
RT   function and expression in tumor cell lines.";
RL   Biochim. Biophys. Acta 1514:291-302(2001).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA], AND ALTERNATIVE
RP   SPLICING (ISOFORM 4).
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F.,
RA   Bloom T., Bruford E., Chang J.L., Cuomo C.A., Eichler E.,
RA   FitzGerald M.G., Jaffe D.B., LaButti K., Nicol R., Park H.-S.,
RA   Seaman C., Sougnez C., Yang X., Zimmer A.R., Zody M.C., Birren B.W.,
RA   Nusbaum C., Fujiyama A., Hattori M., Rogers J., Lander E.S.,
RA   Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 3).
RC   TISSUE=Lung, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   PROTEIN SEQUENCE OF 1-17; 146-171; 227-245; 304-313; 440-451; 511-525
RP   AND 593-630, ACETYLATION AT MET-1, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Cervix carcinoma;
RA   Bienvenut W.V., Lao L., Ryan K.L.;
RL   Submitted (OCT-2009) to UniProtKB.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 83-209 (ISOFORM 4).
RC   TISSUE=Lung carcinoma;
RA   Strausberg R.L.;
RL   Submitted (SEP-2000) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   PROTEIN SEQUENCE OF 112-122; 148-160; 227-245; 248-255; 288-298;
RP   304-313; 440-451; 511-524 AND 593-625, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=B-cell lymphoma;
RA   Bienvenut W.V.;
RL   Submitted (MAR-2005) to UniProtKB.
RN   [12]
RP   FUNCTION, SUBUNIT, INHIBITION, AND MUTAGENESIS OF CYS-210 AND CYS-431.
RX   PubMed=9829974; DOI=10.1074/jbc.273.49.32437;
RA   Torrents D., Estevez R., Pineda M., Fernandez E., Lloberas J.,
RA   Shi Y.-B., Zorzano A., Palacin M.;
RT   "Identification and characterization of a membrane protein (y+L amino
RT   acid transporter-1) that associates with 4F2hc to encode the amino
RT   acid transport activity y+L. A candidate gene for lysinuric protein
RT   intolerance.";
RL   J. Biol. Chem. 273:32437-32445(1998).
RN   [13]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9751058; DOI=10.1038/26246;
RA   Mastroberardino L., Spindler B., Pfeiffer R., Skelly P.J., Loffing J.,
RA   Shoemaker C.B., Verrey F.;
RT   "Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a
RT   permease family.";
RL   Nature 395:288-291(1998).
RN   [14]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=9878049; DOI=10.1093/emboj/18.1.49;
RA   Pfeiffer R., Rossier G., Spindler B., Meier C., Kuehn L.C., Verrey F.;
RT   "Amino acid transport of y+L-type by heterodimers of 4F2hc/CD98 and
RT   members of the glycoprotein-associated amino acid transporter
RT   family.";
RL   EMBO J. 18:49-57(1999).
RN   [15]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10903140; DOI=10.1042/bj3490787;
RA   Broeer A., Wagner C.A., Lang F., Broeer S.;
RT   "The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates
RT   arginine efflux in exchange with glutamine.";
RL   Biochem. J. 349:787-795(2000).
RN   [16]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=11311135;
RA   Broeer A., Friedrich B., Wagner C.A., Fillon S., Ganapathy V.,
RA   Lang F., Broeer S.;
RT   "Association of 4F2hc with light chains LAT1, LAT2 or y+LAT2 requires
RT   different domains.";
RL   Biochem. J. 355:725-731(2001).
RN   [17]
RP   FUNCTION, SUBUNIT, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11389679; DOI=10.1042/0264-6021:3560719;
RA   Ritchie J.W.A., Taylor P.M.;
RT   "Role of the System L permease LAT1 in amino acid and iodothyronine
RT   transport in placenta.";
RL   Biochem. J. 356:719-725(2001).
RN   [18]
RP   SUBUNIT, INTERACTION WITH BETA-1 INTEGRINS, AND MUTAGENESIS OF CYS-210
RP   AND CYS-431.
RX   PubMed=11696247; DOI=10.1186/1472-2091-2-10;
RA   Kolesnikova T.V., Mannion B.A., Berditchevski F., Hemler M.E.;
RT   "Beta1 integrins show specific association with CD98 protein in low
RT   density membranes.";
RL   BMC Biochem. 2:10-10(2001).
RN   [19]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=11564694; DOI=10.1210/endo.142.10.8418;
RA   Friesema E.C.H., Docter R., Moerings E.P.C.M., Verrey F.,
RA   Krenning E.P., Hennemann G., Visser T.J.;
RT   "Thyroid hormone transport by the heterodimeric human system L amino
RT   acid transporter.";
RL   Endocrinology 142:4339-4348(2001).
RN   [20]
RP   FUNCTION, SUBCELLULAR LOCATION, TISSUE SPECIFICITY, AND INDUCTION.
RX   PubMed=11742812;
RA   Okamoto Y., Sakata M., Ogura K., Yamamoto T., Yamaguchi M., Tasaka K.,
RA   Kurachi H., Tsurudome M., Murata Y.;
RT   "Expression and regulation of 4F2hc and hLAT1 in human trophoblasts.";
RL   Am. J. Physiol. 282:C196-C204(2002).
RN   [21]
RP   INTERACTION WITH FAM57A/CT120.
RX   PubMed=12270127; DOI=10.1016/S0006-291X(02)02227-1;
RA   He X.H., Di Y., Li J., Xie Y., Tang Y., Zhang F., Wei L., Zhang Y.,
RA   Qin W.X., Huo K., Li Y., Wan D.F., Gu J.R.;
RT   "Molecular cloning and characterization of CT120, a novel membrane-
RT   associated gene involved in amino acid transport and glutathione
RT   metabolism.";
RL   Biochem. Biophys. Res. Commun. 297:528-536(2002).
RN   [22]
RP   FUNCTION.
RX   PubMed=12117417; DOI=10.1042/BJ20020841;
RA   Simmons-Willis T.A., Koh A.S., Clarkson T.W., Ballatori N.;
RT   "Transport of a neurotoxicant by molecular mimicry: the methylmercury-
RT   L-cysteine complex is a substrate for human L-type large neutral amino
RT   acid transporter (LAT) 1 and LAT2.";
RL   Biochem. J. 367:239-246(2002).
RN   [23]
RP   FUNCTION, SUBUNIT, AND SUBCELLULAR LOCATION.
RX   PubMed=12225859; DOI=10.1016/S0005-2736(02)00516-3;
RA   Kim D.K., Kanai Y., Choi H.W., Tangtrongsup S., Chairoungdua A.,
RA   Babu E., Tachampa K., Anzai N., Iribe Y., Endou H.;
RT   "Characterization of the system L amino acid transporter in T24 human
RT   bladder carcinoma cells.";
RL   Biochim. Biophys. Acta 1565:112-121(2002).
RN   [24]
RP   MASS SPECTROMETRY.
RC   TISSUE=Mammary cancer;
RX   PubMed=11840567;
RX   DOI=10.1002/1615-9861(200202)2:2<212::AID-PROT212>3.0.CO;2-H;
RA   Harris R.A., Yang A., Stein R.C., Lucy K., Brusten L., Herath A.,
RA   Parekh R., Waterfield M.D., O'Hare M.J., Neville M.A., Page M.J.,
RA   Zvelebil M.J.;
RT   "Cluster analysis of an extensive human breast cancer cell line
RT   protein expression map database.";
RL   Proteomics 2:212-223(2002).
RN   [25]
RP   FUNCTION, SUBUNIT, AND TISSUE SPECIFICITY.
RX   PubMed=14603368; DOI=10.1113/eph8802647;
RA   Arancibia-Garavilla Y., Toledo F., Casanello P., Sobrevia L.;
RT   "Nitric oxide synthesis requires activity of the cationic and neutral
RT   amino acid transport system y+L in human umbilical vein endothelium.";
RL   Exp. Physiol. 88:699-710(2003).
RN   [26]
RP   FUNCTION, SUBUNIT, INTERACTION WITH ICAM1, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=12716892; DOI=10.1074/jbc.M302777200;
RA   Liu X., Charrier L., Gewirtz A., Sitaraman S., Merlin D.;
RT   "CD98 and intracellular adhesion molecule I regulate the activity of
RT   amino acid transporter LAT-2 in polarized intestinal epithelia.";
RL   J. Biol. Chem. 278:23672-23677(2003).
RN   [27]
RP   GLYCOSYLATION AT ASN-365; ASN-381 AND ASN-424.
RX   PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [28]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=15980244; DOI=10.1167/iovs.04-1175;
RA   Tomi M., Mori M., Tachikawa M., Katayama K., Terasaki T., Hosoya K.;
RT   "L-type amino acid transporter 1-mediated L-leucine transport at the
RT   inner blood-retinal barrier.";
RL   Invest. Ophthalmol. Vis. Sci. 46:2522-2530(2005).
RN   [29]
RP   FUNCTION, AND SUBUNIT.
RX   PubMed=15769744; DOI=10.1074/jbc.M413164200;
RA   Li S., Whorton A.R.;
RT   "Identification of stereoselective transporters for S-nitroso-L-
RT   cysteine: role of LAT1 and LAT2 in biological activity of S-
RT   nitrosothiols.";
RL   J. Biol. Chem. 280:20102-20110(2005).
RN   [30]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-381 AND ASN-424.
RC   TISSUE=Plasma;
RX   PubMed=16335952; DOI=10.1021/pr0502065;
RA   Liu T., Qian W.-J., Gritsenko M.A., Camp D.G. II, Monroe M.E.,
RA   Moore R.J., Smith R.D.;
RT   "Human plasma N-glycoproteome analysis by immunoaffinity subtraction,
RT   hydrazide chemistry, and mass spectrometry.";
RL   J. Proteome Res. 4:2070-2080(2005).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [32]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=16496379; DOI=10.1002/ijc.21866;
RA   Nawashiro H., Otani N., Shinomiya N., Fukui S., Ooigawa H., Shima K.,
RA   Matsuo H., Kanai Y., Endou H.;
RT   "L-type amino acid transporter 1 as a potential molecular target in
RT   human astrocytic tumors.";
RL   Int. J. Cancer 119:484-492(2006).
RN   [33]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS].
RC   TISSUE=Melanoma;
RX   PubMed=17081065; DOI=10.1021/pr060363j;
RA   Chi A., Valencia J.C., Hu Z.-Z., Watabe H., Yamaguchi H.,
RA   Mangini N.J., Huang H., Canfield V.A., Cheng K.C., Yang F., Abe R.,
RA   Yamagishi S., Shabanowitz J., Hearing V.J., Wu C., Appella E.,
RA   Hunt D.F.;
RT   "Proteomic and bioinformatic characterization of the biogenesis and
RT   function of melanosomes.";
RL   J. Proteome Res. 5:3135-3144(2006).
RN   [34]
RP   PHOSPHORYLATION AT SER-406; SER-408; SER-410; SER-527 AND SER-531.
RX   PubMed=19065266; DOI=10.1371/journal.pone.0003895;
RA   Nguyen H.T.T., Dalmasso G., Yan Y., Obertone T.S., Sitaraman S.V.,
RA   Merlin D.;
RT   "Ecto-phosphorylation of CD98 regulates cell-cell interactions.";
RL   PLoS ONE 3:E3895-E3895(2008).
RN   [35]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [36]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381 AND ASN-506.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [37]
RP   GLYCOSYLATION AT ASN-424.
RX   PubMed=19139490; DOI=10.1074/mcp.M800504-MCP200;
RA   Jia W., Lu Z., Fu Y., Wang H.P., Wang L.H., Chi H., Yuan Z.F.,
RA   Zheng Z.B., Song L.N., Han H.H., Liang Y.M., Wang J.L., Cai Y.,
RA   Zhang Y.K., Deng Y.L., Ying W.T., He S.M., Qian X.H.;
RT   "A strategy for precise and large scale identification of core
RT   fucosylated glycoproteins.";
RL   Mol. Cell. Proteomics 8:913-923(2009).
RN   [38]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-365; ASN-381; ASN-424 AND
RP   ASN-506.
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19349973; DOI=10.1038/nbt.1532;
RA   Wollscheid B., Bausch-Fluck D., Henderson C., O'Brien R., Bibel M.,
RA   Schiess R., Aebersold R., Watts J.D.;
RT   "Mass-spectrometric identification and relative quantification of N-
RT   linked cell surface glycoproteins.";
RL   Nat. Biotechnol. 27:378-386(2009).
RN   [39]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-165, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [40]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [41]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2),
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE
RP   OF INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [42]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2 (ISOFORM 2), CLEAVAGE OF
RP   INITIATOR METHIONINE [LARGE SCALE ANALYSIS] (ISOFORM 2), AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [43]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT MET-1, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [44]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-103; SER-134 AND
RP   SER-165, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [45]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [46]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-166, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [47]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M.,
RA   Ayoub D., Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (2.1 ANGSTROMS) OF 212-630, SUBUNIT, MUTAGENESIS
RP   OF CYS-210, SUBCELLULAR LOCATION, AND DISULFIDE BOND.
RX   PubMed=17724034; DOI=10.1074/jbc.M704524200;
RA   Fort J., de la Ballina L.R., Burghardt H.E., Ferrer-Costa C.,
RA   Turnay J., Ferrer-Orta C., Uson I., Zorzano A., Fernandez-Recio J.,
RA   Orozco M., Lizarbe M.A., Fita I., Palacin M.;
RT   "The structure of human 4F2hc ectodomain provides a model for
RT   homodimerization and electrostatic interaction with plasma membrane.";
RL   J. Biol. Chem. 282:31444-31452(2007).
CC   -!- FUNCTION: Required for the function of light chain amino-acid
CC       transporters. Involved in sodium-independent, high-affinity
CC       transport of large neutral amino acids such as phenylalanine,
CC       tyrosine, leucine, arginine and tryptophan. Involved in guiding
CC       and targeting of LAT1 and LAT2 to the plasma membrane. When
CC       associated with SLC7A6 or SLC7A7 acts as an arginine/glutamine
CC       exchanger, following an antiport mechanism for amino acid
CC       transport, influencing arginine release in exchange for
CC       extracellular amino acids. Plays a role in nitric oxide synthesis
CC       in human umbilical vein endothelial cells (HUVECs) via transport
CC       of L-arginine. Required for normal and neoplastic cell growth.
CC       When associated with SLC7A5/LAT1, is also involved in the
CC       transport of L-DOPA across the blood-brain barrier, and that of
CC       thyroid hormones triiodothyronine (T3) and thyroxine (T4) across
CC       the cell membrane in tissues such as placenta. Involved in the
CC       uptake of methylmercury (MeHg) when administered as the L-cysteine
CC       or D,L-homocysteine complexes, and hence plays a role in metal ion
CC       homeostasis and toxicity. When associated with SLC7A5 or SLC7A8,
CC       involved in the cellular activity of small molecular weight
CC       nitrosothiols, via the stereoselective transport of L-
CC       nitrosocysteine (L-CNSO) across the transmembrane. Together with
CC       ICAM1, regulates the transport activity LAT2 in polarized
CC       intestinal cells, by generating and delivering intracellular
CC       signals. When associated with SLC7A5, plays an important role in
CC       transporting L-leucine from the circulating blood to the retina
CC       across the inner blood-retinal barrier.
CC       {ECO:0000269|PubMed:10903140, ECO:0000269|PubMed:11311135,
CC       ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:11742812,
CC       ECO:0000269|PubMed:12117417, ECO:0000269|PubMed:12225859,
CC       ECO:0000269|PubMed:12716892, ECO:0000269|PubMed:14603368,
CC       ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:15980244,
CC       ECO:0000269|PubMed:9751058, ECO:0000269|PubMed:9829974,
CC       ECO:0000269|PubMed:9878049}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=295 uM for glutamine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=236 uM for leucine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=120 uM for arginine (in the presence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC         KM=138 uM for arginine (in the absence of NaCl)
CC         {ECO:0000269|PubMed:10903140};
CC   -!- SUBUNIT: Disulfide-linked heterodimer of a glycosylated heavy
CC       chain and a non-glycosylated light chain (SLC7A5, SLC7A6, SLCA7A7,
CC       SLC7A8, SLC7A10 or SLCA7A11). Colocalizes with cadherins (By
CC       similarity). Interacts with FAM57A/CT120 and ICAM1. Constitutively
CC       and specifically associates with beta-1 integrins (alpha-2/beta-1,
CC       alpha-3/beta-1, alpha-5/beta-1 and alpha-6/beta-1), but minimally
CC       with alpha-4/beta-1. {ECO:0000250, ECO:0000269|PubMed:11311135,
CC       ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11564694, ECO:0000269|PubMed:11696247,
CC       ECO:0000269|PubMed:12225859, ECO:0000269|PubMed:12270127,
CC       ECO:0000269|PubMed:12716892, ECO:0000269|PubMed:14603368,
CC       ECO:0000269|PubMed:15769744, ECO:0000269|PubMed:17724034,
CC       ECO:0000269|PubMed:9751058, ECO:0000269|PubMed:9829974,
CC       ECO:0000269|PubMed:9878049}.
CC   -!- SUBCELLULAR LOCATION: Apical cell membrane; Single-pass type II
CC       membrane protein. Melanosome. Note=Identified by mass spectrometry
CC       in melanosome fractions from stage I to stage IV. Localized to the
CC       plasma membrane when associated with SLC7A5 or SLC7A8. Localized
CC       to the placental apical membrane. Located selectively at cell-cell
CC       adhesion sites (By similarity). Colocalized with SLC7A8/LAT2 at
CC       the basolateral membrane of kidney proximal tubules and small
CC       intestine epithelia. Expressed in both luminal and abluminal
CC       membranes of brain capillary endothelial cells (By similarity).
CC       {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=P08195-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P08195-2; Sequence=VSP_037907;
CC         Note=Initiator Met-1 is removed. Contains a N-acetylserine at
CC         position 2. Contains a phosphoserine at position 2.
CC         {ECO:0000244|PubMed:19413330, ECO:0000244|PubMed:21406692,
CC         ECO:0000244|PubMed:22223895};
CC       Name=3;
CC         IsoId=P08195-3; Sequence=VSP_037908;
CC       Name=4;
CC         IsoId=P08195-4; Sequence=VSP_037909;
CC   -!- TISSUE SPECIFICITY: Expressed ubiquitously in all tissues tested
CC       with highest levels detected in kidney, placenta and testis and
CC       weakest level in thymus. During gestation, expression in the
CC       placenta was significantly stronger at full-term than at the mid-
CC       trimester stage. Expressed in HUVECS and at low levels in resting
CC       peripheral blood T-lymphocytes and quiescent fibroblasts. Also
CC       expressed in fetal liver and in the astrocytic process of primary
CC       astrocytic gliomas. Expressed in retinal endothelial cells and in
CC       the intestinal epithelial cell line C2BBe1.
CC       {ECO:0000269|PubMed:11389679, ECO:0000269|PubMed:11557028,
CC       ECO:0000269|PubMed:11742812, ECO:0000269|PubMed:12716892,
CC       ECO:0000269|PubMed:14603368, ECO:0000269|PubMed:15980244,
CC       ECO:0000269|PubMed:16496379, ECO:0000269|PubMed:3265470,
CC       ECO:0000269|PubMed:3480538}.
CC   -!- INDUCTION: Expression is induced in resting peripheral blood T-
CC       lymphocytes following PHA stimulation. Expression increases at the
CC       time of maximal DNA synthesis, in fibroblasts stimulated to
CC       divide. Expression and the uptake of leucine is stimulated in
CC       mononuclear, cytotrophoblast-like choriocarcinoma cells by
CC       combined treatment with PMA and calcium ionophore.
CC       {ECO:0000269|PubMed:11742812, ECO:0000269|PubMed:3265470,
CC       ECO:0000269|PubMed:3480538}.
CC   -!- PTM: Phosphorylation on Ser-406; Ser-408 or Ser-410 and on Ser-527
CC       or Ser-531 by ecto-protein kinases favors heterotypic cell-cell
CC       interactions. {ECO:0000269|PubMed:19065266}.
CC   -!- MASS SPECTROMETRY: Mass=57944.93; Method=MALDI; Range=1-529;
CC       Evidence={ECO:0000269|PubMed:11840567};
CC   -!- MISCELLANEOUS: Arginine uptake is inhibited by increasing
CC       concentrations of leucine in the presence of Na(+).
CC   -!- SIMILARITY: Belongs to the SLC3A transporter family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; J02939; AAA52497.1; -; mRNA.
DR   EMBL; J02769; AAA51540.1; -; mRNA.
DR   EMBL; J03569; AAA35536.1; -; mRNA.
DR   EMBL; M21904; AAA35489.1; -; Genomic_DNA.
DR   EMBL; M21898; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21899; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21900; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21901; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21902; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; M21903; AAA35489.1; JOINED; Genomic_DNA.
DR   EMBL; AB018010; BAA84649.1; -; mRNA.
DR   EMBL; AP001160; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC001061; AAH01061.2; -; mRNA.
DR   EMBL; BC003000; AAH03000.2; -; mRNA.
DR   EMBL; BE794697; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS31589.1; -. [P08195-3]
DR   CCDS; CCDS31590.1; -. [P08195-2]
DR   CCDS; CCDS8039.2; -. [P08195-1]
DR   PIR; A28455; SAHU4F.
DR   RefSeq; NP_001012680.1; NM_001012662.2.
DR   RefSeq; NP_001012682.1; NM_001012664.2. [P08195-3]
DR   RefSeq; NP_001013269.1; NM_001013251.2. [P08195-2]
DR   RefSeq; NP_002385.3; NM_002394.5. [P08195-1]
DR   UniGene; Hs.502769; -.
DR   PDB; 2DH2; X-ray; 2.10 A; A=212-630.
DR   PDB; 2DH3; X-ray; 2.80 A; A/B=212-630.
DR   PDBsum; 2DH2; -.
DR   PDBsum; 2DH3; -.
DR   ProteinModelPortal; P08195; -.
DR   SMR; P08195; -.
DR   BioGrid; 112411; 49.
DR   IntAct; P08195; 39.
DR   MINT; MINT-4999018; -.
DR   STRING; 9606.ENSP00000367123; -.
DR   GuidetoPHARMACOLOGY; 890; -.
DR   CAZy; GH13; Glycoside Hydrolase Family 13.
DR   TCDB; 8.A.9.2.2; the rbat transport accessory protein (rbat) family.
DR   iPTMnet; P08195; -.
DR   PhosphoSitePlus; P08195; -.
DR   SwissPalm; P08195; -.
DR   BioMuta; SLC3A2; -.
DR   DMDM; 257051063; -.
DR   EPD; P08195; -.
DR   MaxQB; P08195; -.
DR   PaxDb; P08195; -.
DR   PeptideAtlas; P08195; -.
DR   PRIDE; P08195; -.
DR   DNASU; 6520; -.
DR   Ensembl; ENST00000338663; ENSP00000340815; ENSG00000168003. [P08195-2]
DR   Ensembl; ENST00000377889; ENSP00000367121; ENSG00000168003. [P08195-3]
DR   Ensembl; ENST00000377890; ENSP00000367122; ENSG00000168003. [P08195-1]
DR   GeneID; 6520; -.
DR   KEGG; hsa:6520; -.
DR   UCSC; uc001nwd.4; human. [P08195-1]
DR   CTD; 6520; -.
DR   DisGeNET; 6520; -.
DR   GeneCards; SLC3A2; -.
DR   HGNC; HGNC:11026; SLC3A2.
DR   HPA; CAB010455; -.
DR   HPA; HPA017980; -.
DR   MIM; 158070; gene.
DR   neXtProt; NX_P08195; -.
DR   OpenTargets; ENSG00000168003; -.
DR   PharmGKB; PA35894; -.
DR   eggNOG; KOG0471; Eukaryota.
DR   eggNOG; COG0366; LUCA.
DR   GeneTree; ENSGT00870000136466; -.
DR   HOGENOM; HOG000233529; -.
DR   HOVERGEN; HBG000023; -.
DR   InParanoid; P08195; -.
DR   KO; K06519; -.
DR   PhylomeDB; P08195; -.
DR   BioCyc; MetaCyc:ENSG00000168003-MONOMER; -.
DR   Reactome; R-HSA-210991; Basigin interactions.
DR   Reactome; R-HSA-352230; Amino acid transport across the plasma membrane.
DR   Reactome; R-HSA-71240; Tryptophan catabolism.
DR   SABIO-RK; P08195; -.
DR   ChiTaRS; SLC3A2; human.
DR   EvolutionaryTrace; P08195; -.
DR   GeneWiki; SLC3A2; -.
DR   GenomeRNAi; 6520; -.
DR   PRO; PR:P08195; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   Bgee; ENSG00000168003; -.
DR   CleanEx; HS_SLC3A2; -.
DR   ExpressionAtlas; P08195; baseline and differential.
DR   Genevisible; P08195; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; NAS:UniProtKB.
DR   GO; GO:0042470; C:melanosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0005432; F:calcium:sodium antiporter activity; TAS:UniProtKB.
DR   GO; GO:0003824; F:catalytic activity; IEA:InterPro.
DR   GO; GO:0003725; F:double-stranded RNA binding; IDA:MGI.
DR   GO; GO:0015175; F:neutral amino acid transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IDA:UniProtKB.
DR   GO; GO:0006865; P:amino acid transport; TAS:UniProtKB.
DR   GO; GO:0006816; P:calcium ion transport; NAS:UniProtKB.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0016049; P:cell growth; NAS:UniProtKB.
DR   GO; GO:0060356; P:leucine import; ISS:UniProtKB.
DR   GO; GO:0050900; P:leukocyte migration; TAS:Reactome.
DR   GO; GO:0043330; P:response to exogenous dsRNA; IMP:MGI.
DR   GO; GO:0006569; P:tryptophan catabolic process; TAS:Reactome.
DR   GO; GO:0015827; P:tryptophan transport; ISS:UniProtKB.
DR   InterPro; IPR006047; Glyco_hydro_13_cat_dom.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   InterPro; IPR031984; SLC3A2_N.
DR   Pfam; PF00128; Alpha-amylase; 1.
DR   Pfam; PF16028; SLC3A2_N; 1.
DR   SMART; SM00642; Aamy; 1.
DR   SUPFAM; SSF51445; SSF51445; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Amino-acid transport;
KW   Cell membrane; Complete proteome; Direct protein sequencing;
KW   Disulfide bond; Glycoprotein; Isopeptide bond; Membrane;
KW   Phosphoprotein; Reference proteome; Signal-anchor; Transmembrane;
KW   Transmembrane helix; Transport; Ubl conjugation.
FT   CHAIN         1    630       4F2 cell-surface antigen heavy chain.
FT                                /FTId=PRO_0000064383.
FT   TOPO_DOM    102    184       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    185    205       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM    206    630       Extracellular. {ECO:0000255}.
FT   MOD_RES       1      1       N-acetylmethionine.
FT                                {ECO:0000244|PubMed:22814378,
FT                                ECO:0000269|Ref.9}.
FT   MOD_RES     103    103       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     106    106       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q794F9}.
FT   MOD_RES     134    134       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     165    165       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     406    406       Phosphoserine.
FT                                {ECO:0000305|PubMed:19065266}.
FT   MOD_RES     408    408       Phosphoserine.
FT                                {ECO:0000305|PubMed:19065266}.
FT   MOD_RES     410    410       Phosphoserine.
FT                                {ECO:0000305|PubMed:19065266}.
FT   MOD_RES     527    527       Phosphoserine.
FT                                {ECO:0000305|PubMed:19065266}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000305|PubMed:19065266}.
FT   CARBOHYD    365    365       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    381    381       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    424    424       N-linked (GlcNAc...) (complex)
FT                                asparagine. {ECO:0000269|PubMed:12754519,
FT                                ECO:0000269|PubMed:16335952,
FT                                ECO:0000269|PubMed:19139490,
FT                                ECO:0000269|PubMed:19349973}.
FT   CARBOHYD    506    506       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:19159218,
FT                                ECO:0000269|PubMed:19349973}.
FT   DISULFID    210    210       Interchain (with light chain).
FT                                {ECO:0000269|PubMed:17724034}.
FT   CROSSLNK    147    147       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in ubiquitin).
FT   CROSSLNK    166    166       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO2).
FT                                {ECO:0000244|PubMed:25114211}.
FT   VAR_SEQ       1    101       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:11557028,
FT                                ECO:0000303|PubMed:3036867,
FT                                ECO:0000303|PubMed:3476959,
FT                                ECO:0000303|PubMed:3480538}.
FT                                /FTId=VSP_037907.
FT   VAR_SEQ      38     99       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037908.
FT   VAR_SEQ      98     98       V -> VTETGFHHVSQADIEFLTSIDPTASASGSAGI (in
FT                                isoform 4). {ECO:0000303|Ref.10}.
FT                                /FTId=VSP_037909.
FT   MUTAGEN     210    210       C->S: Abolishes dimerization, leucine
FT                                uptake and interaction with beta-1
FT                                integrins. {ECO:0000269|PubMed:11696247,
FT                                ECO:0000269|PubMed:17724034,
FT                                ECO:0000269|PubMed:9829974}.
FT   MUTAGEN     431    431       C->S: No effect on dimerization, leucine
FT                                uptake or interaction with beta-1
FT                                integrins. {ECO:0000269|PubMed:11696247,
FT                                ECO:0000269|PubMed:9829974}.
FT   CONFLICT    137    137       G -> E (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    158    158       A -> P (in Ref. 3; AAA51540).
FT                                {ECO:0000305}.
FT   CONFLICT    223    223       A -> P (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    315    315       E -> D (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    320    320       S -> F (in Ref. 5; AAA35489).
FT                                {ECO:0000305}.
FT   CONFLICT    372    372       E -> G (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    412    413       GE -> PQ (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    465    465       V -> L (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    481    481       G -> P (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    549    549       G -> E (in Ref. 5; AAA35489).
FT                                {ECO:0000305}.
FT   CONFLICT    609    609       L -> P (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   CONFLICT    612    612       E -> G (in Ref. 4; AAA35536).
FT                                {ECO:0000305}.
FT   HELIX       218    220       {ECO:0000244|PDB:2DH2}.
FT   STRAND      224    227       {ECO:0000244|PDB:2DH2}.
FT   HELIX       230    234       {ECO:0000244|PDB:2DH2}.
FT   HELIX       241    245       {ECO:0000244|PDB:2DH2}.
FT   HELIX       248    253       {ECO:0000244|PDB:2DH2}.
FT   STRAND      257    261       {ECO:0000244|PDB:2DH2}.
FT   STRAND      265    267       {ECO:0000244|PDB:2DH2}.
FT   STRAND      275    280       {ECO:0000244|PDB:2DH2}.
FT   HELIX       282    284       {ECO:0000244|PDB:2DH2}.
FT   HELIX       287    299       {ECO:0000244|PDB:2DH2}.
FT   STRAND      303    307       {ECO:0000244|PDB:2DH2}.
FT   TURN        310    313       {ECO:0000244|PDB:2DH2}.
FT   STRAND      314    316       {ECO:0000244|PDB:2DH2}.
FT   STRAND      319    321       {ECO:0000244|PDB:2DH3}.
FT   HELIX       323    340       {ECO:0000244|PDB:2DH2}.
FT   STRAND      344    347       {ECO:0000244|PDB:2DH2}.
FT   HELIX       350    352       {ECO:0000244|PDB:2DH2}.
FT   HELIX       356    370       {ECO:0000244|PDB:2DH2}.
FT   STRAND      375    379       {ECO:0000244|PDB:2DH2}.
FT   HELIX       385    391       {ECO:0000244|PDB:2DH2}.
FT   TURN        392    394       {ECO:0000244|PDB:2DH2}.
FT   STRAND      399    401       {ECO:0000244|PDB:2DH2}.
FT   TURN        404    407       {ECO:0000244|PDB:2DH2}.
FT   HELIX       412    426       {ECO:0000244|PDB:2DH2}.
FT   STRAND      437    439       {ECO:0000244|PDB:2DH3}.
FT   HELIX       441    443       {ECO:0000244|PDB:2DH2}.
FT   HELIX       447    449       {ECO:0000244|PDB:2DH2}.
FT   HELIX       450    457       {ECO:0000244|PDB:2DH2}.
FT   STRAND      460    467       {ECO:0000244|PDB:2DH2}.
FT   HELIX       470    472       {ECO:0000244|PDB:2DH2}.
FT   HELIX       476    478       {ECO:0000244|PDB:2DH2}.
FT   STRAND      479    481       {ECO:0000244|PDB:2DH2}.
FT   STRAND      484    486       {ECO:0000244|PDB:2DH2}.
FT   HELIX       493    495       {ECO:0000244|PDB:2DH3}.
FT   HELIX       500    502       {ECO:0000244|PDB:2DH3}.
FT   HELIX       505    507       {ECO:0000244|PDB:2DH2}.
FT   HELIX       509    513       {ECO:0000244|PDB:2DH2}.
FT   HELIX       519    532       {ECO:0000244|PDB:2DH2}.
FT   HELIX       534    538       {ECO:0000244|PDB:2DH2}.
FT   STRAND      540    545       {ECO:0000244|PDB:2DH2}.
FT   STRAND      550    556       {ECO:0000244|PDB:2DH2}.
FT   STRAND      562    568       {ECO:0000244|PDB:2DH2}.
FT   STRAND      570    572       {ECO:0000244|PDB:2DH2}.
FT   STRAND      581    583       {ECO:0000244|PDB:2DH2}.
FT   HELIX       585    587       {ECO:0000244|PDB:2DH2}.
FT   STRAND      591    603       {ECO:0000244|PDB:2DH2}.
FT   STRAND      607    610       {ECO:0000244|PDB:2DH2}.
FT   HELIX       611    613       {ECO:0000244|PDB:2DH2}.
FT   STRAND      621    626       {ECO:0000244|PDB:2DH2}.
SQ   SEQUENCE   630 AA;  67994 MW;  AE427F8204CC10B0 CRC64;
     MELQPPEASI AVVSIPRQLP GSHSEAGVQG LSAGDDSELG SHCVAQTGLE LLASGDPLPS
     ASQNAEMIET GSDCVTQAGL QLLASSDPPA LASKNAEVTG TMSQDTEVDM KEVELNELEP
     EKQPMNAASG AAMSLAGAEK NGLVKIKVAE DEAEAAAAAK FTGLSKEELL KVAGSPGWVR
     TRWALLLLFW LGWLGMLAGA VVIIVRAPRC RELPAQKWWH TGALYRIGDL QAFQGHGAGN
     LAGLKGRLDY LSSLKVKGLV LGPIHKNQKD DVAQTDLLQI DPNFGSKEDF DSLLQSAKKK
     SIRVILDLTP NYRGENSWFS TQVDTVATKV KDALEFWLQA GVDGFQVRDI ENLKDASSFL
     AEWQNITKGF SEDRLLIAGT NSSDLQQILS LLESNKDLLL TSSYLSDSGS TGEHTKSLVT
     QYLNATGNRW CSWSLSQARL LTSFLPAQLL RLYQLMLFTL PGTPVFSYGD EIGLDAAALP
     GQPMEAPVML WDESSFPDIP GAVSANMTVK GQSEDPGSLL SLFRRLSDQR SKERSLLHGD
     FHAFSAGPGL FSYIRHWDQN ERFLVVLNFG DVGLSAGLQA SDLPASASLP AKADLLLSTQ
     PGREEGSPLE LERLKLEPHE GLLLRFPYAA
//
